Condition
PKP2-ARVC
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Recruiting1
Active Not Recruiting1
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07050160Enrolling By Invitation
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
NCT06109181Phase 1Active Not Recruiting
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
NCT06976606Recruiting
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
Showing all 3 trials